日本語 
Eisai Co., Ltd. and Nuvation Bio Inc. have pushed taletrectinib into the next stage in Europe. The European Medicines Agency has validated the application. That basically means the file is complete and now it moves into a full review under the standard timeline.
This is not a fresh drug entering the system for the first time. Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer. In the U.S. and Japan, it is sold as IBTROZI. In China, it is marketed as DOVBLERON. So the groundwork is already there. Europe is the next obvious step.
The drug targets a specific mutation. ROS1-positive cases sit at around 2 percent of non-small cell lung cancer. The European lung cancer epidemic appears to be a minor problem until its actual scale becomes evident. The annual diagnosis rate reaches 400000 cases with non-small cell lung cancer accounting for most of the cases. So even a niche segment is still meaningful.
Also Read: transcosmos partners Tokyo University on pharmacist gap
The data behind this filing comes from the TRUST-I and TRUST-II studies. These are Phase 2 trials run across global patient groups. Results have already been published, and more updated data with longer follow-up is expected soon. That matters because regulators look for consistency over time, not just early response.
There is also a business angle sitting underneath this. In early 2026, Eisai and Nuvation put their pen on their papers to spread the availability of taletrectinib over multiple regions outside from the U.S., China, and Japan. Europe falls right into that plan. After this, they are lining up filings in the U.K., Canada, and other markets within Eisai’s licensed territories.
So this is not just one approval attempt. It is part of a broader rollout. The drug is already in circulation in key markets. Now it is about getting it cleared in the remaining big regions and building a wider presence step by step.
English